Reorganization at Eisai: Yasuno named CEO of U.S. division
Plus: National Pharmaceutical Council hires ICER SVP, and updates from Verily, TheracosBio and more
Eisai Co. Ltd. (Tokyo:4523) announced the integration of its Alzheimer’s disease and brain health clinical development functions with its deep human biology learning organization, a change accompanied by several updates to its leadership. SVP, Chief Strategy & Planning Officer and Chief Ecosystem Officer Keisuke Naito is now also global Alzheimer’s disease officer. SVP Tatsuyuki Yasuno has become president, America’s region and chairman and CEO of Eisai Inc. Naito and Yasuno were already serving in their new roles in an acting capacity. Lynn Kramer, who was VP, Chief Clinical Officer, Alzheimer’s Disease and Brain Health, is now VP and chief clinical officer.
The changes coincide with the July 31 retirement of Ivan Cheung, who was chairman and CEO of Eisai Inc. and who led the development and launch preparations for Leqembi lecanemab-irmb. ...